Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary Zhaoke Ophthalmology Ltd. (HKG: 6622) a distribution and supply agreement with Malaysian pharmaceutical corporation Pharmaniaga. The agreement pertains to Zhaoke’s generic version of AbbVie’s Ganfort, a combination of bimatoprost and timolol maleate eye drops used for the treatment of open-angle glaucoma and high intraocular pressure.
This generic version marks a significant advancement in the treatment options for patients in China, where it became the first of its kind to pass the generic quality consistency evaluation in February 2023. It is particularly beneficial for patients who have not responded well to single therapy with receptor blockers or prostaglandin analogues. The original drug was granted marketing approval in China back in September 2013.
According to the terms of the agreement, Pharmaniaga will acquire non-exclusive distribution rights for the product in Malaysia. The company is set to register the drug under its own trade name and will handle all aspects of the drug’s lifecycle in the country, including importation, promotion, distribution, marketing, and sales.- Flcube.com
